NCT02150824 - Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin | Biotech Hunter

Enrollment

103

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

Placebo

BI 187004 high dose matching placebo once daily

DRUG

Placebo

BI 187004 medium dose matching placebo once daily

DRUG

Placebo

BI 187004 high dose matching placebo once daily add on to background metformin

DRUG

BI 187004

BI 187004 high dose once daily add on to background metformin

DRUG

Placebo

BI 187004 low dose matching placebo once daily

DRUG

BI 187004

BI 187004 medium dose once daily

DRUG

BI 187004

BI 187004 low dose once daily

DRUG

BI 187004

BI 187004 high dose once daily

Trial Locations (3)

1307.4.49003 Boehringer Ingelheim Investigational Site, Berlin

1307.4.49002 Boehringer Ingelheim Investigational Site, Mainz

1307.4.49001 Boehringer Ingelheim Investigational Site, Neuss